Connect Biopharma Holdings Ltd — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Barry D. Quart (CEO, Pharm.D.) and Lisa Peraza (SVP Finance) certified the Form 10-Q for the quarterly period ended June 30, 2026, filed August 12, 2026. Both officers certify that disclosure controls and internal control over financial reporting are effective, financial statements fairly present the company's condition and operations, and no material weaknesses or fraud involving management were identified.
Why this rating
Routine SOX 302/906 certification; standard periodic disclosure with no material weaknesses flagged. No business developments disclosed in provided exhibits alone.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.